AbbVie Inc. buy Biotechhunter
Start price
26.06.20
/
50%
€86.60
Target price
31.07.20
-
Performance (%)
-6.96%
End price
31.07.20
€80.57
Summary
This prediction ended on 31.07.20 with a price of €80.57. With a performance of -6.96%, the BUY prediction by Biotechhunter finished with a loss. Dividends of €1.04 are taken into consideration when calculating the performance. Biotechhunter has 50% into this predictionAbbVie (ABBV) is a multinational biopharmaceutical company based in North Chicago, Illinois. It was spun off as a separate entity from Abbott Laboratories in 2013 and is primarily focused on the development and commercialization of drugs for the treatment of conditions such as immunology, oncology, and neuroscience. Its key product is Humira, which is used to treat a range of autoimmune diseases, generating a significant portion of the company's revenue. The company also has a pipeline of promising products in various stages of development, making it a reputable player in the pharmaceutical industry.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| AbbVie Inc. | -0.909% | -0.909% | 6.410% | 71.797% |
| iShares Core DAX® | -1.670% | -1.001% | 10.864% | 12.563% |
| iShares Nasdaq 100 | -4.184% | -1.145% | 37.458% | 41.078% |
| iShares Nikkei 225® | -4.967% | -5.783% | 18.828% | 0.655% |
| iShares S&P 500 | -2.834% | -0.572% | 25.875% | 39.960% |
Comments by Biotechhunter for this prediction
In the thread AbbVie Inc. diskutieren
Buy AbbVie Inc.